Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool

通过在远程患者监测工具中集成数字化生物标志物即时检测，增强 COPD 患者的分层

• 批准号: 10098600
• 金额: $ 62.58万
• 依托单位: PROAXSIS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10098600
• 关键词: Enhanced; stratification; COPD; patients; via

The enzyme Neutrophil Elastase (NE) is associated with the severity of several respiratory diseases, including Chronic Obstructive Pulmonary Disease (COPD), where repeated cycles of infection and inflammation leads to active NE release from immune cells, causing lung damage. Active NE is predictive of lung function loss and is the most informative biomarker to monitor disease activity.ProAxsis has developed a novel point-of-care test (NEATstik) which allows active NE to be quickly measured within 10 minutes. Researchers in Dundee have shown that a positive NEATstik test identifies patients suffering from a lung bacterial infection, who are most likely to benefit from antibiotics. Additionally, they used NEATstik to identify patients at highest risk of suffering from exacerbations over the following year. Thus, NEATstik can support appropriate antibiotic prescribing, and monitoring of their effect, to ensure that respiratory disease patients receive the treatment that is most likely to work for them.An additional key advantage of NEATstik is that it could be used in the patient's home, thereby avoiding unnecessary trips to hospital, a key consideration in the post-COVID environment. To make this viable, enhancements are needed for the sample processing required for conduct of the test. Further valuable information could be gained if the NEATstik result was combined with other respiratory health measures. This is a collaborative project between ProAxsis Limited, who developed NEATstik, the Centre for Process and Innovation (CPI), a world-renowned product engineering expert centre and Wanda Health, specialists in integrating new technologies into remote patient monitoring systems. Together, the partners will significantly enhance the sample processing required for NEATstik, and integrate the test alongside multiple other respiratory health measures into a remote patient monitoring tool, allowing patients to conduct the test at home, and their healthcare professionals to observe the NEATstik test result alongside other important health data.

中性粒细胞弹性蛋白酶（NE）与多种呼吸道疾病的严重程度有关，包括慢性阻塞性肺部疾病（COPD），其中反复的感染和炎症导致免疫细胞的活跃NE释放，从而导致肺损伤。活跃的NE可以预测肺功能丧失，并且是监测疾病活动的最有用的生物标志物。Proaxsis开发了一种新型的护理测试（NEATSTIK），该测试允许在10分钟内快速测量活动性NE。邓迪的研究人员表明，Neatstik阳性测试确定患有肺部细菌感染的患者，这些患者最有可能从抗生素中受益。此外，他们使用Neatstik来识别次年患痛苦最高风险的患者。因此，NeatStik可以支持适当的抗生素处方并监测其作用，以确保呼吸道疾病患者接受最有可能对他们有用的治疗方法。Neatstik的其他关键优势在于，它可以在患者的家中使用，从而避免不必要的旅行去医院，这是后环境中的关键考虑。为了使这一可行，需要增强测试所需的样品处理。如果将Neatstik结果与其他呼吸健康措施结合使用，则可以获得进一步的有价值的信息。这是Proaxsis Limited（Proaxsis Limited）的一个协作项目，他开发了Neatstik，neatstik，neatstik，过程与创新中心（CPI），一个世界知名的产品工程专家中心和万达健康（Wanda Health），将新技术集成到远程患者监测系统中。合作伙伴一起将显着增强NEATSTIK所需的样本处理，并将测试与其他多种呼吸健康措施相结合到远程患者监测工具中，从而使患者可以在家中进行测试，其医疗保健专业人员可以观察NeatStik测试结果以及其他重要的健康数据。